The Wegovy Tablet: What Self-Funded Employers and Their Brokers Need to Know

# The Wegovy Tablet: What Self-Funded Employers and Their Brokers Need to Know

I'll admit it... I didn't realize Wegovy was now available in a tablet until I saw the Super Bowl commercial on Sunday. And if I didn't know, I'm guessing millions of employees didn't either. But thanks to the Super Bowl, now they do — and you can bet HR teams and benefit managers are going to start hearing: "Hey, is our plan covering the Wegovy pill now?"

And honestly, this changes a lot for both employees and self-funded employers.

The FDA approved the oral Wegovy pill in December 2025, giving people a true non-injectable option for the first time. For many who were interested in the weight loss benefits, the biggest barrier wasn't access or cost — it was the needle. Let's face it... how many people want to inject themselves if they don't have to? Removing that hurdle means more employees will be willing to start therapy.

## The Upsides

**Better Adherence & Lower Barriers** — A pill eliminates injection anxiety, meaning more people will actually start therapy and stick with it.

**Lower Cash Price** — Oral Wegovy is significantly cheaper than the injectable, at least via cash pricing. The tablet runs roughly $149–$299/month compared to $1,349/month list price for the injectable. That difference introduces real downward pricing pressure across the entire GLP-1 category.

**No Refrigeration or Special Handling** — No cold-chain logistics, less waste, and fewer delays. That's helpful for both employees and plans.

**More Competition Is Coming** — Wegovy's move into oral GLP-1s accelerates the competitive landscape, with other manufacturers developing pills as well.

**Better Outcomes, Better Well-Being** — If starting therapy is easier, more employees will do it — leading to improved weight, metabolic health, and overall wellness.

## The Downsides for Plans

But here's where brokers need to help their clients think clearly, because the upsides come with real cost implications.

**Higher Utilization = Higher Total Spend** — The tablet removes major friction (no needles, easier initiation), which means more members will start therapy. That could translate to significantly higher total Rx spend for employers — even if the per-unit cost is lower.

**PBM Pricing May Not Follow Cash Pricing** — Even though the tablet's cash price sits well below the injectable, PBM prices rarely mirror the cash market. Rebate incentives and formulary structures mean employers may not see the same savings at the plan level.

**Coverage Decisions Get Harder** — Employers now must consider two forms of Wegovy with different costs, utilization behaviors, and clinical patterns. The formulary conversation just got more complex.

**Expect More Employee Pressure** — The Super Bowl just educated the country. Employees are going to ask about this, and benefit teams need to be ready with a clear answer.

## Strategic Options for Employers

This is where the broker's role becomes critical. Here are two paths worth discussing with your clients:

**Option A — Tablet-First Coverage:** If PBM pricing is favorable, employers may steer members to the tablet before the injectable. This captures the adherence benefits while managing per-unit costs.

**Option B — Exclude Weight-Loss GLP-1s Entirely:** With cash prices already in the $150–$300 range, some employers may choose to let members self-fund GLP-1s for weight loss — keeping the plan focused on medically necessary indications while employees access the tablet on their own at a manageable out-of-pocket cost.

Either way, the conversation needs to happen now — not after the claims start rolling in.